Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

177Lu-J-591 shows promising antitumor activity at the MTD of 70 mCi/m2

Feb. 18, 2013

Roche presents potential predictivity of preclinical cancer models

Feb. 18, 2013

Peregrine Pharmaceuticals reports results from phase II bavituximab trial

Feb. 14, 2013

ImmunoGen achieves patient enrollment milestone in phase II NORTH trial

Feb. 13, 2013

TG Therapeutics opens expansion cohorts in trial of ublituximab

Feb. 12, 2013

First patient treated in phase I trial of GL-ONC1

Feb. 7, 2013

Seattle Genetics begins two phase I trials of SGN-CD19A

Feb. 7, 2013

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Feb. 7, 2013

Health Canada grants approval to Adcetris for two lymphoma indications

Feb. 4, 2013

Teva Pharmaceutical terminates agreements with CureTech

Feb. 4, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...